Last 23 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.42 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 26.58 | 5.41 | 1.73 | 5.03 | 1.74 | 2.03 | 3.54 | 4.66 | 5.12 | 4.84 | 15.78 | 27.44 | 11.23 |
| — | +166.0% | -51.3% | +7.9% | -66.0% | -58.0% | -77.6% | -83.0% | -54.5% | -84.0% | -65.3% | -47.9% | -75.7% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | 76.26 | 104.87 | 14.78 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 77.75 | 6.69 | 2.42 | 4.29 | 10.88 | 5.91 | 26.83 | 5.49 | — | 8.52 | — | — | — |
| — | +13.2% | -91.0% | -21.8% | — | -30.6% | — | — | — | -93.4% | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Scilex Holding Company's operating margin was -1766.2% in Q3 2025, down 1559.0 pp QoQ and down 1628.2 pp YoY. The trailing four-quarter average of -680.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 7.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.5% | 68.5% | 66.9% | 72.3% | 68.5% | 73.9% | 73.2% | 64.7% | 58.7% | 66.5% | 66.8% | 66.1% | 62.1% |
| — | -7.3% | -8.5% | +11.8% | +16.7% | +11.2% | +9.6% | -2.0% | -5.5% | -2.6% | -17.2% | -20.6% | -28.5% | |
| Operating Margin | -147.4% | -1766.2% | -207.2% | -557.5% | -190.5% | -138.0% | -95.4% | -179.0% | -136.2% | -383.6% | -181.3% | -240.7% | -165.6% |
| — | -1180.2% | -117.1% | -211.5% | -39.8% | +64.0% | +47.4% | +25.7% | +17.7% | -311.1% | -25.3% | -86.2% | -31.4% | |
| Net Margin | -128.7% | -2435.9% | -869.7% | -521.2% | -43.4% | -30.4% | -229.6% | -224.0% | -159.0% | -351.2% | -211.8% | -290.6% | -150.0% |
| — | -7913.9% | -278.8% | -132.7% | +72.7% | +91.3% | -8.4% | +22.9% | -5.9% | -285.8% | +5.9% | -116.5% | +70.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | -248.0% | -130.0% | -49.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -75.0% | -143.1% | -105.8% | -30.3% | -6.7% | -4.3% | -38.4% | -25.3% | -23.5% | -34.3% | -25.1% | -35.6% | -20.4% |
| — | -3241.2% | -175.5% | -19.8% | +71.6% | +87.5% | -53.1% | +29.0% | -15.4% | -242.7% | -40.5% | -266.2% | +47.1% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | -110.9% | -73.0% | -41.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | -151.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 67.6% YoY to 0.05x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 3.62 | 0.98 | 0.04 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.16 | 0.05 | 0.11 | 0.10 | 0.16 | 0.14 | 0.20 | 0.15 | 0.19 | 0.11 | 0.67 | 0.48 | 0.66 |
| — | -67.6% | -44.2% | -30.3% | -14.4% | +27.0% | -70.5% | -69.0% | -71.7% | -11.1% | +349.1% | +52.0% | +386.3% | |
| Quick Ratio | 0.15 | 0.04 | 0.10 | 0.09 | 0.15 | 0.13 | 0.19 | 0.14 | 0.17 | 0.09 | 0.64 | 0.45 | 0.63 |
| — | -67.7% | -45.1% | -31.3% | -11.4% | +41.2% | -71.0% | -69.6% | -73.0% | -22.5% | +345.5% | +45.9% | +421.8% | |
| Interest Coverage | -42.48 | -66.66 | -7.65 | -11.24 | -99.57 | -34.58 | -27.36 | -36.68 | -33.28 | -75.64 | -4562.80 | — | -19.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonScilex Holding Company's current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Scilex Holding Company's current operating margin is -147.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Scilex Holding Company's business trajectory between earnings reports.